ConsideRAte Study - Splenic Stimulation for RA
- Conditions
- Rheumatoid Arthritis
- Interventions
- Registration Number
- NCT05003310
- Lead Sponsor
- Galvani Bioelectronics
- Brief Summary
This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and accessories. The study will consist of 4 study periods, including a Randomized Control Trial period (Period 1), an Open Label period (Period 2), a Treat-to-target period (Period 3), and a Long-term Follow-up period (Period 4). Participants eligible for implant will have active rheumatoid arthritis (RA) and have an inadequate response or intolerance to at least two biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) or JAK inhibitors (JAKis). A sufficient number of participants will be enrolled so that approximately 28 participants will undergo device implantation.
- Detailed Description
Participants with active rheumatoid arthritis (RA) who receive the implantable system will be randomly assigned to receive either active stimulation or sham-stimulation for 12 weeks (Period 1).
Following Period 1, all participants will enter an open label phase (Period 2) during which participants who responded to stimulation will continue on stimulation; whereas participants who received sham stimulation, or were stimulation non-responders, will receive a market-approved RA drug for 12 weeks.
At the end of Period 2, participants who respond to their Period 2 therapy but still exhibit signs and symptoms of RA will enter the Treat-to-target period (Period 3); others will proceed to Period 4 (Long-term Follow-up). During the Treat-to-Target period, participants will be treated with dual therapy (stimulation in combination with the market-approved RA drug) for up to 24 weeks.
Period 4 provides long term safety follow up for all study participants for a period of 5 years. Participants may receive stimulation in combination with other approved and standard of care therapies, subject to a favorable benefit-risk assessment in the judgement of the treating rheumatologist.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 28
- RA of at least six months duration, per 2010 ACR/EULAR criteria
- Male or female participants, 22-75 years of age
- Active RA
- Inadequate Response to at least 2 biologic DMARDs and/or JAK-inhibitors (JAKis) including at least one TNF inhibitor
- Have an appropriate washout from previously used biological DMARDs or JAKi
- Receiving current treatment with standard dose(s) of conventional synthetic DMARD(s) or have documented history of failure due to ineffectiveness or intolerance
- Inability to provide informed consent
- Significant psychiatric disease or substance abuse
- History of unilateral or bilateral vagotomy
- Active or latent tuberculosis
- Known infection with human immunodeficiency virus (HIV); current acute or chronic hepatitis B or hepatitis C; previous hepatitis B
- Positive SARS COV 2 PCR screening test for COVID-19 infection (at the point of screening for this study)
- Currently implanted electrically active medical devices (e.g., cardiac pacemakers, automatic implantable cardioverter-defibrillators)
- Previous splenectomy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Sham Stimulation; Period 1 Background Treatment Sham stimulation for 12 weeks Active Stimulation; Period 1 Background Treatment Active stimulation for 12 weeks Sham Stimulation; Period 1 Sham Stimulation Sham stimulation for 12 weeks Active stimulation combined with RA drug, Period 3 Background Treatment Participants on active stimulation during Period 2 will have baricitinib added for 24 weeks Open label active stimulation, Period 2 Background Treatment Open label active stimulation for 12 additional weeks RA drug combined with active stimulation, Period 3 Active Stimulation Participants on baricitinib during Period 2 will have active stimulation added for 24 weeks Active stimulation combined with RA drug, Period 3 Active Stimulation Participants on active stimulation during Period 2 will have baricitinib added for 24 weeks Open label active stimulation, Period 2 Active Stimulation Open label active stimulation for 12 additional weeks Active Stimulation; Period 1 Active Stimulation Active stimulation for 12 weeks Open label RA Drug, Period 2 Background Treatment Open label drug treatment with baricitinib for 12 weeks RA drug combined with active stimulation, Period 3 Background Treatment Participants on baricitinib during Period 2 will have active stimulation added for 24 weeks Active stimulation combined with RA drug, Period 3 Baricitinib Participants on active stimulation during Period 2 will have baricitinib added for 24 weeks Long-term Follow-up, Period 4 Active Stimulation Standard of care treatments with or without stimulation Long-term Follow-up, Period 4 Background Treatment Standard of care treatments with or without stimulation RA drug combined with active stimulation, Period 3 Baricitinib Participants on baricitinib during Period 2 will have active stimulation added for 24 weeks Open label RA Drug, Period 2 Baricitinib Open label drug treatment with baricitinib for 12 weeks
- Primary Outcome Measures
Name Time Method Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] During Period 4 (Period 4 is up to 5 years in duration beyond Period 3) Incidence of Adverse Events [Safety and Tolerability] Up through the end of Period 1 (Period 1 is up to 12 weeks duration) Adverse Events (AEs) may include clinically significant findings from Laboratory Safety Assessments (clinical chemistry and hematology), vital signs (blood pressure, heart rate, respiratory rate, and body temperature), and 12-Lead EKG
- Secondary Outcome Measures
Name Time Method Change in Health Assessment Questionnaire Disability Index (HAQ-DI) score Baseline to 12 weeks (Period 1) Change in the 28 Joint Disease Activity Score 28 - C reactive protein (DAS28-CRP) Baseline to 12 weeks (Period 1) To evaluate the usability of the external Galvani System devices and accessories Through 48 weeks Summarize feedback collected on a questionnaire pertaining to the use of the external Galvani System devices
Change in the level of LPS-inducible release of TNFα in whole blood assay Baseline to 24 weeks (Period 2) Change in the level of LPS-inducible release of IL-17 in whole blood assay Baseline to 24 weeks (Period 2) Change in SF-36 mental component score Baseline to 48 weeks (Period 3) Change in SF-36 physical component score Baseline to 48 weeks (Period 3) Change in SF-36 domain score Baseline to 48 weeks (Period 3) Evaluate device performance as assessed by tabulation of device deficiencies Through 48 weeks Incidence of a change in DAS28-CRP greater than 1.2 units in participants who are given Drug treatment with baricitinib during Period 2 week 12 to week 24 Incidence of participants who are given drug treatment with baricitinib achieving DAS28-CRP score <2.6 at the end of Period 2 Week 24 Change in the level of Lipopolysaccharide (LPS)-inducible release of Tumor Necrosis Factor (TNFα) in whole blood assay Baseline to 12 weeks (Period 1) Change in the level of LPS-inducible release of Interleukin 6 (IL-6) in whole blood assay Baseline to 24 weeks (Period 2) Change in the level of LPS-inducible release of IL-8 in whole blood assay Baseline to 24 weeks (Period 2) Change in DAS28-CRP Baseline to 48 weeks (Period 3) Change in HAQ-DI score Baseline to 48 weeks (Period 3) Change in Short Form 36 (SF-36) physical component score Baseline to 12 weeks (Period 1) To evaluate the participants' perception of therapy and sensation Through 48 weeks A form is provided to participants at each visit after randomization to describe any sensations that may be associated with the Galvani System
Change in DAS28-CRP in participants who remain on active stimulation during Period 2 week 12 to week 24 Incidence of participants who remain on active stimulation achieving DAS28-CRP score <2.6 at the end of Period 2 Time Frame: Week 24 Change in DAS28-CRP in participants who are given Drug treatment with baricitinib during Period 2 week 12 to week 24
Trial Locations
- Locations (14)
Academic Medical Center (AMC) Dept of Rheumatology & Clinical Immunology
🇳🇱Amsterdam, Netherlands
Maxima Medical Center, MMC
🇳🇱Eindhoven, Netherlands
Medvin Research - Whittier
🇺🇸Whittier, California, United States
Pinnacle Research Group, LLC
🇺🇸Anniston, Alabama, United States
The Osteoporosis & Clinical Trials Center
🇺🇸Hagerstown, Maryland, United States
Medvin Research - Covina
🇺🇸Covina, California, United States
Oregon Health & Science University
🇺🇸Portland, Oregon, United States
Altoona Center for Clinical Research
🇺🇸Altoona, Pennsylvania, United States
NYU Langone
🇺🇸Brooklyn, New York, United States
Arthritis & Rheumatology Institute
🇺🇸Allen, Texas, United States
St. David's Healthcare
🇺🇸Austin, Texas, United States
Metroplex Clinical Research Center
🇺🇸Dallas, Texas, United States
Tekton Research
🇺🇸Austin, Texas, United States
Southwest Rheumatology Research
🇺🇸Mesquite, Texas, United States